- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07284121
En studie for å evaluere pasientrapportert tilfredshet, effektivitet og sikkerhet av atezolizumab hos deltakere behandlet i rutinemessig klinisk praksis
En ikke-intervensjonell, multicenter, multikohortstudie for å evaluere pasientrapportert tilfredshet, effektivitet og sikkerhet av subkutan atezolizumab hos deltakere behandlet i rutinemessig klinisk praksis
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Studer Kontakt Backup
- Navn: Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. and Canada)
- E-post: global-roche-genentech-trials@gene.com
Studiesteder
-
-
-
Auderghem, Belgia, 1160
- Rekruttering
- CHIREC
-
Ghent, Belgia, 9000
- Rekruttering
- AZ Sint Lucas (Sint Lucas)
-
Haine-Saint-Paul, Belgia, 7100
- Rekruttering
- CHU HELORA - Hôpital de la Louvière - Site Jolimont
-
Liège, Belgia, 4000
- Rekruttering
- CHC MontLégia
-
Merksem, Belgia, 2170
- Rekruttering
- ZNA Jan Palfijn
-
Mont-godinne, Belgia, 5530
- Rekruttering
- CHU UCL Mont-Godinne
-
-
-
-
-
Panagyurishte, Bulgaria, 4500
- Rekruttering
- Multiprofile Hospital for Active Treatment Uni Hospital
-
Rousse, Bulgaria, 7000
- Rekruttering
- Complex Oncological Center-Ruse EOOD
-
Sofia, Bulgaria, 1431
- Rekruttering
- UMHAT "Sv. Ivan Rilski", EAD
-
Sofia, Bulgaria, 1632
- Rekruttering
- MBAL Serdika EOOD
-
Sofia, Bulgaria, 1407
- Rekruttering
- Tokuda Hospital
-
Sofia, Bulgaria, 1527
- Rekruttering
- UMHAT Tsaritsa Yoanna - ISUL
-
Sofia, Bulgaria, 1797
- Rekruttering
- MHAT SofiaMed
-
-
-
-
Apulia
-
Lecce, Apulia, Italia, 73044
- Rekruttering
- Presidio Ospedaliero Vito Fazzi
-
-
Campania
-
Naples, Campania, Italia, 80131
- Rekruttering
- AORN Ospedali dei Colli Ospedale Monaldi
-
Naples, Campania, Italia, 80131
- Rekruttering
- Az. Osp. Cardarelli
-
-
Emilia-Romagna
-
Modena, Emilia-Romagna, Italia, 41100
- Rekruttering
- A.O. Universitaria Policlinico Di Modena
-
Ravenna, Emilia-Romagna, Italia, 48100
- Rekruttering
- Ospedale Provinciale Santa Maria Delle Croci
-
-
Lazio
-
Rome, Lazio, Italia, 00168
- Rekruttering
- Policlinico Universitario Agostino Gemelli
-
Rome, Lazio, Italia, 128
- Rekruttering
- Università Campus Bio-Medico di Roma
-
-
Liguria
-
Genoa, Liguria, Italia, 16132
- Rekruttering
- IRCCS AOU San Martino - IST
-
-
Lombardy
-
Bergamo, Lombardy, Italia, 24125
- Rekruttering
- Cliniche Gavazzeni SpA Humanitas Gavazzeni
-
Milan, Lombardy, Italia, 20142
- Rekruttering
- Asst Santi Paolo E Carlo
-
Milan, Lombardy, Italia, 20122
- Rekruttering
- Fondazione IRCCS Ospedale Maggiore Policlinico
-
Milan, Lombardy, Italia, 20122
- Rekruttering
- Ospedale Maggiore Policlinico
-
-
Piedmont
-
Acquaviva Delle Fonti, Piedmont, Italia, 70021
- Rekruttering
- Ente Ecclesiastico Ospedale Generale Regionale F Miulli
-
Novara, Piedmont, Italia, 28100
- Rekruttering
- A.O.U. Maggiore della Carità
-
-
Sardinia
-
Sassari, Sardinia, Italia, 07100
- Rekruttering
- Azienda Ospedaliero Universitaria Di Sassari
-
-
Sicily
-
Misterbianco (CT), Sicily, Italia, 95045
- Rekruttering
- Humanitas Istituto Clinico Catanese S.p.A
-
Palermo, Sicily, Italia, 90146
- Rekruttering
- Casa di Cura La Maddalena
-
Palermo, Sicily, Italia, 90100
- Rekruttering
- A.O.U. Policlinico Paolo Giaccone
-
-
The Marches
-
Fano (PU), The Marches, Italia, 61032
- Rekruttering
- Azienda Sanitaria Territoriale Pesaro Urbino (AST PU) - Ospedale Santa Croce;UOC Oncologia - Stabilimento di Fano
-
-
Trentino-Alto Adige
-
Trento, Trentino-Alto Adige, Italia, 38100
- Rekruttering
- Ospedale Santa Chiara
-
-
Veneto
-
Mestre, Veneto, Italia, 30174
- Rekruttering
- Ospedale dell'Angelo
-
Verona, Veneto, Italia, 37126
- Rekruttering
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Krakow, Polen, 31-115
- Rekruttering
- Narodowy Instytut Onkologii - Panstwowy Instytut Badawczy, Oddzia? w Krakowie
-
Lublin, Polen, 20-954
- Rekruttering
- Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
-
Olsztyn, Polen, 10-357
- Rekruttering
- Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
-
Poznan, Polen, 60-569
- Rekruttering
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
-
Słupsk, Polen, 76-200
- Rekruttering
- Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka
-
Tomaszów Mazowiecki, Polen, 97-200
- Rekruttering
- NU-MED Centrum Diagnostyki i Terapii Onkologicznej
-
-
-
-
-
Bucharest, Romania, 022328
- Rekruttering
- Institutul Clinic Fundeni Bucuresti
-
Bucharest, Romania, 022328
- Rekruttering
- Institut Oncologic Prof. Dr. Alexandru Trestioreanu
-
Bucharest, Romania, 011356
- Rekruttering
- Spitalul Clinic de Urgenta Prof. Dr. Agrippa Ionescu
-
Cluj-Napoca, Romania, 400162
- Rekruttering
- Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor
-
Galati, Romania, 800578
- Rekruttering
- Spitalul Clinic Jude?ean de Urgen?? Sfântul Apostol Andrei Galati;oncology
-
Iași, Romania, 700483
- Rekruttering
- Institutul Regional de Oncologie Iasi
-
Ploieşti, Romania, 107071
- Rekruttering
- Spitalul Municipal Ploiesti
-
Satu Mare, Romania, 440055
- Rekruttering
- Spitalul Judetean de Urgenta Satu Mare
-
Timișoara, Romania, 300239
- Rekruttering
- Oncomed SRL
-
-
-
-
-
Albacete, Spania, 02006
- Rekruttering
- Complejo Hospitalario Universitario de Albacete
-
Alicante, Spania, 3010
- Rekruttering
- Hospital General Univ. de Alicante
-
Alicante, Spania, 03010
- Rekruttering
- Hospital General de Alicante;servicio de digestivo
-
Badajoz, Spania, 06080
- Rekruttering
- Hospital de Badajoz
-
Barcelona, Spania, 08036
- Rekruttering
- Hospital Clinic I Provincial
-
Barcelona, Spania, 08041
- Rekruttering
- Hospital de la Santa Creu i Sant Pau
-
Ciudad Real, Spania, 13005
- Rekruttering
- Hospital General de Ciudad Real
-
Granada, Spania, 18016
- Rekruttering
- Hospital Universitario San Cecilio
-
Guadalajara, Spania, 19002
- Rekruttering
- Hospital General Universitario de Guadalajara
-
Murcia, Spania, 30008
- Rekruttering
- Hospital General Universitario J.M Morales Meseguer
-
Murcia, Spania, 30120
- Rekruttering
- Hospital Virgen de Arrixaca;servicio de digestivo
-
Pontevedra, Spania, 36002
- Rekruttering
- Complejo Hospitalario de Pontevedra
-
Seville, Spania, 41013
- Rekruttering
- Hospital Virgen del Rocio;Servicio de digestivo
-
Toledo, Spania, 45007
- Rekruttering
- Hospital de Toledo;Servicio de digestivo
-
Toledo, Spania, 47007
- Rekruttering
- Hospital de Toledo;servicio de oncologia
-
Valencia, Spania, 46015
- Rekruttering
- Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia
-
Valladolid, Spania, 47005
- Rekruttering
- Hospital Clinico Universitario Valladolid
-
Valladolid, Spania, 47003
- Rekruttering
- Hospital Clinico Universitario de Valladolid
-
Zaragoza, Spania, 50009
- Rekruttering
- Hospital Universitario Miguel Servet
-
-
Almeria
-
Almería, Almeria, Spania, 04009
- Rekruttering
- Complejo Hospitalario Torrecardenas
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spania, 7120
- Rekruttering
- Hospital Son Espases
-
-
Barcelona
-
Manresa, Barcelona, Spania, 08243
- Rekruttering
- Hospital Sant Joan de Deu de Manresa;Servicio oncologia
-
-
Cadiz
-
Puerto Real, Cadiz, Spania, 11510
- Rekruttering
- Hospital Universitario Puerto Real
-
-
Ciudad REAL
-
Alcázar de San Juan, Ciudad REAL, Spania, 13600
- Rekruttering
- Hospital Universitario Mancha Centro (Alcázar de San Juan);Servicio de digestivo
-
Alcázar de San Juan, Ciudad REAL, Spania, 13600
- Rekruttering
- Hospital Universitario Mancha Centro (Alcázar de San Juan);Servicio de oncología
-
-
LA Coruna
-
Santiago de Compostela, LA Coruna, Spania, 15706
- Rekruttering
- Complejo Hospitalario Universitario de Santiago (CHUS)
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spania, 33006
- Rekruttering
- Hospital Univ. Central de Asturias
-
Oviedo, Principality of Asturias, Spania, 33011
- Rekruttering
- Hospital Univ. Central de Asturias
-
-
Tarragona
-
Reus, Tarragona, Spania, 43204
- Rekruttering
- Hospital Universitari Sant Joan de Reus
-
-
Tenerife
-
Santa Cruz de Tenerife, Tenerife, Spania, 38320
- Rekruttering
- Hospital Universitario de Canarias
-
Santa Cruz de Tenerife, Tenerife, Spania, 38010
- Rekruttering
- Complejo Hospitalario Nuestra Señora de la Candelaria
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spania, 48903
- Rekruttering
- Hospital de Cruces
-
Bilbao, Vizcaya, Spania, 48903
- Rekruttering
- Hospital de Cruces
-
-
-
-
-
Birmingham, Storbritannia, B15 2TH
- Rekruttering
- University Hospitals Birmingham NHS Foundation Trust
-
Guildford, Storbritannia, GU2 7XX
- Rekruttering
- Royal Surrey County Hospital
-
Leeds, Storbritannia, LS9 7TF
- Rekruttering
- Leeds Teaching Hosp NHS Trust
-
Middlesbrough, Storbritannia, TS4 3BW
- Rekruttering
- James Cook University Hospital
-
Norfolk, Storbritannia, NR31 6LA
- Rekruttering
- James Paget University Hospitals NHS Foundation Trust
-
-
-
-
-
Krems, Østerrike, 3500
- Rekruttering
- Universitätsklinikum Krems
-
Linz, Østerrike, 4020
- Rekruttering
- Ordensklinikum Linz Elisabethinen
-
Vienna, Østerrike, 1210
- Rekruttering
- Krankenhaus Nord - Klinik Floridsdorf
-
Wels, Østerrike, 4600
- Rekruttering
- Klinikum Wels-Grieskirchen
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with PD-L1 expression of >= 50% on TC, participants diagnosed with metastatic NSCLC with PD-L1 expression of ≥ 50% on TC who have not received prior systemic therapy for metastatic disease, participants diagnosed with ES-SCLC who have not previously been treated, and participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.
Beskrivelse
Inclusion Criteria:
-
Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
- Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC
- Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated
- Extensive-stage small cell lung cancer (ES-SCLC) not previously treated
- Advanced or unresectable HCC not previously treated with systemic therapy
-
Should not have received > 4 prior cycles of IV Atezolizumab
Exclusion Criteria:
- Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling
- Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label
- Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program
- Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Cohort 1: Early Non-small Cell Lung Cancer (NSCLC)
Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with Programmed Cell-Death Ligand 1 (PD-L1) expression of >= 50% on Tumor Cell (TC). |
Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.
Andre navn:
|
|
Cohort 2: Metastatic NSCLC
Participants diagnosed with metastatic NSCLC with PD-L1 expression of >= 50% on TC who have not received prior systemic therapy for metastatic disease. |
Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.
Andre navn:
|
|
Cohort 3: Extensive stage small cell lung cancer (ES-SCLC)
Participants diagnosed with ES-SCLC who have not previously been treated. |
Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.
Andre navn:
|
|
Cohort 4: Hepatocellular Carcinoma (HCC)
Participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy. |
Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Terapiadministrasjon tilfredshetsspørreskjema subkutan (TASQ-SC) score
Tidsramme: Ved syklus 2 og syklus 3 (hver syklus varighet/lengde er 3 uker)
|
Ved syklus 2 og syklus 3 (hver syklus varighet/lengde er 3 uker)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Total overlevelse (OS)
Tidsramme: Indeksdato opptil ca. 3,5 år
|
Indeksdato opptil ca. 3,5 år
|
|
OS ved 2 år
Tidsramme: Etter indeksdato opp til 2 år
|
Etter indeksdato opp til 2 år
|
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Score
Tidsramme: Grunnlinje- eller indeksdato
|
Grunnlinje- eller indeksdato
|
|
Prosentandel deltakere med bivirkninger
Tidsramme: Opptil cirka 3,5 år
|
Opptil cirka 3,5 år
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Lungesykdommer
- Leversykdommer
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Neoplasmer i leveren
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom
- Karsinom, hepatocellulært
- Lungeneoplasmer
- Atezolizumab
Andre studie-ID-numre
- MO45893
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .